U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06793189) titled 'MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL' on Jan. 20.
Brief Summary: Marginal zone lymphoma (MZL) is a common type of indolent lymphoma that originates from the marginal zone of lymphoid follicles. This study aims to evaluate targeted therapy based on the prognostic risk stratification of MZL-IPI in newly diagnosed MZL cases requiring systemic treatment, and provides a basis for precision treatment of MZL.
Study Start Date: Jan. 21
Study Type: INTERVENTIONAL
Condition:
Marginal Zone Lymphoma(MZL)
Intervention:
DRUG: Obinutuzumab and Orelabrutinib
Induction: Obinutuzumab (1000 mg on days 1, 8, and 15 of cycle 1; ...